<DOC>
	<DOC>NCT02756338</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and feasibility of performing the BioMonitor 2 insertion procedure in an office setting.</brief_summary>
	<brief_title>BioMonitor 2 In-Office Setting Insertion Safety and Feasibility Evaluation With Device Functionality Assessment</brief_title>
	<detailed_description />
	<criteria>Indicated for continuous monitoring with an insertable cardiac monitor Willing to be implanted in an office setting with only local anesthetic available Able to understand the nature of the study and provide informed consent Able and willing to complete all routine followup visits at the study site for the expected 90day followup Able and willing to use a CardioMessengerÂ® capable of communicating with the BioMonitor 2 Age greater than or equal to 18 years At the time of insertion, the following preprocedure criteria must be met for the subject to undergo insertion: Most recent INR value (within 7 days) is less than 3.5 if currently taking warfarin Absence of infection with no history of infection within the last 30 days Compromised immune system or at high risk of developing an infection Abnormal thoracic anatomy or scar tissue at the implant site that may adversely impact the insertion procedure Enrolled in any investigational cardiac device trial Currently indicated for or implanted with a pacemaker, ICD device, or hemodynamic monitoring system Currently implanted with an ICM or ILR Life expectancy less than 6 months Patients reporting pregnancy at the time of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>